As the largest IPO in 2025, Medline’s performance is particularly noteworthy. Since its IPO offering price until January 9th, Medline’s stock price has surged nearly 40%. The company, which primarily manufactures and distributes medical products such as gloves, surgical gowns, and examination tables, has now reached a market capitalization of $57 billion. In Monday’s trading session, Medline’s stock (MDLN) saw a significant increase, closing up 5.43% at $42.72. This extends the strong upward trend the company has maintained since completing its $7.2 billion initial public offering last month.
Wall Street analysts generally hold a bullish tone regarding Medline’s business model and growth prospects. Data shows that a total of 27 institutions have initiated coverage on the stock, with 22 assigning a “Buy” or equivalent rating. The average 12-month price target set by analysts is $47.12 per share. The core strengths cited by analysts include the company’s scale, vertically integrated manufacturing model, and the structural tailwind from an aging population. Analysts at investment bank William Blair emphasized that Medline is a leader in the medical surgical distribution field, with its business covering a total addressable market of up to $375 billion, of which the US market is approximately $175 billion. Currently, the company has only penetrated about 15% of this market opportunity. Brandon Vasquez, an analyst at William Blair, pointed out that thanks to the aging population, this market has maintained mid-single-digit growth for decades and is expected to continue this trend for the next 10 years. Data from the US Census Bureau supports this view, projecting that the proportion of US residents aged 65 and over will rise from the current roughly 17% to about 23% by 2050. Additionally, Medline’s multi-year contracts provide clear visibility for its future share growth.
Some analysts hold a relatively cautious stance on Medline’s prospects, primarily due to concerns about the impact of the Trump administration’s tariff policies. Rothschild & Co. Redburn initiated coverage with a $42 price target and a “Neutral” rating, believing that due to tariff-related dilution effects, the company’s profit margin levels are expected to remain largely flat between fiscal years 2025 and 2028. Especially in the second half of fiscal 2025 and 2026, tariffs are expected to exert substantial pressure on margins.
However, other institutions believe the impact of tariffs will gradually dissipate after the short term. Bank of America analysts assigned a $50 price target, citing Medline’s leadership position in US medical surgical manufacturing and distribution. They emphasized that after absorbing tariff-related costs, the company’s organic growth rate is expected to reach the long-term mid-to-high single-digit percentage by 2027, with EBITDA growth also accelerating. Jaiendra Singh, Senior Equity Research Analyst at Truist Securities, set a price target of $52. He highlighted Medline’s manufacturing and distribution network, along with its extensive sourcing and third-party supplier partnerships, arguing that this creates a self-reinforcing cycle that drives product adoption, customer retention, and business expansion. Medline’s management anticipates that the penetration rate of its own brands will increase from the current approximately 35% to 60%.
